Reducing Drug Craving Memories

Not Applicable

• Conditions: Cocaine Addiction
• Interventions: Drug: Inderal

• Registration Number: NCT01319214
• Lead Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre

Brief Summary

The primary objective is to investigate the potential ability of Inderal (propranolol hydrochloride) to diminish the reconsolidation of motivationally potent drug-related cues in cocaine dependent participants. If effective in this laboratory model, Inderal may have clinical efficacy.

Detailed Description

Not available

Study Timeline

• Status Verified: 2011-01
• Study Start: 2011-03
• Study First Submitted: 2011-03-18
• Study First Submitted QC: 2011-03-18
• Study First Posted: 2011-03-21
• Last Update Submitted: 2011-05-18
• Last Update Posted: 2011-05-19
• Primary Completion: 2015-03
• Study Completion: 2015-03

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• 60 psychotropic medication-free men or women (15 subjects x 4 groups) who have met DSM-IV-TR diagnostic criteria for cocaine dependence for the past 6 months (age 18 - 50 years old);
• Minimum of three days cocaine abstinent on study days;
• Primary use of cocaine is intra-nasal or smoked crack

Exclusion Criteria

• Medical conditions that might be aggravated by participation in the study:

  • cardiovascular disorders that might be aggravated by participation in the study: hypotension (SBP: < 100 mmHg), bradycardia (heart rate < 60 /min), severe atrioventricular block (Type II or III), severe hypertension (SBP: > 160 mmHg; DBP: > 100 mmHg), myocardial infarction, history of chest pain and admission to ED for chest pain;
  • respiratory disorders: bronchial asthma and chronic obstructive pulmonary disease;
  • diabetic patients treated with insulin or oral hypoglycemic agents. Propranolol may mask the first signs of a developing hypoglycemia.

• Seropositive pregnancy test

• Comorbidity with current axis I psychiatric disorders other than anxiety, affective and substance use disorders

• Severe liver disfunction

• Current or recent (< 5 half lives) use of medications that may interact with Inderal (see above)

• Positive urine tox screen for barbiturates. Positive breath alcohol screen. {Note: all urine tox screen results will be destroyed immediately after collection. The information will not be stored}

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: FACTORIAL

Arm && Interventions

Group	Intervention	Description
Inderal, neutral cues	Inderal	-
Inderal, drug cues	Inderal	-
Placebo, neutral cues	Inderal	-
Placebo, drug cues	Inderal	-

Primary Outcome Measures

Name	Time	Method
Self-report drug craving	One day and one month post-treatment	One day and one month after the intervention, the investigators will measure drug craving using visual analog scales (VAS) and the Cocaine Craving Questionnaire (CCQ).

Secondary Outcome Measures

Name	Time	Method
Drug use	One month after the intervention	One month after the intervention, participants will be interviewed about their drug and alcohol use